Founded in 2020, Regain Therapeutics is pursuing a new treatment approach for Alzheimer’s disease which focuses on replenishing soluble amyloid-beta peptides in the brain rather than removing the corresponding accumulation of amyloid plaques.

The company has been founded based on research discoveries and patent-pending technologies developed at Karolinska Institute in Sweden in collaboration with The University of Cincinnati in the US. This research indicates that the treatment of Alzheimer’s disease might lie in normalizing the levels of a specific brain protein called amyloid-beta peptide (Aβ42). This protein is needed in its original, soluble form to keep the brain healthy, but sometimes it hardens into clumps, called amyloid plaques. The researchers’ key discovery is that Alzheimer’s disease symptoms seem dependent on the depletion of the normal protein, which is in a soluble state, instead of when it aggregates into plaques. In other words, cognitive impairment could be due to a decline in soluble amyloid-beta peptide instead of the corresponding accumulation of amyloid plaques.

The company’s therapeutic approach for the Alzheimer’s program will focus on replenishing these brain soluble proteins to their normal levels.

Subscribe for alerts on new companies featured on Startups.Bio